EURI B Stock Overview
Manufactures and sells diagnostic assays for the clinical laboratory and point-of-care settings, and point-of-care instrumentation for diagnostic applications in Sweden.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
European Institute of Science AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 4.64 |
52 Week High | SEK 18.00 |
52 Week Low | SEK 1.60 |
Beta | 2.09 |
11 Month Change | 70.59% |
3 Month Change | 8.92% |
1 Year Change | -71.57% |
33 Year Change | -96.61% |
5 Year Change | -98.47% |
Change since IPO | -99.83% |
Recent News & Updates
Shareholder Returns
EURI B | SE Biotechs | SE Market | |
---|---|---|---|
7D | -5.3% | -5.0% | -7.2% |
1Y | -71.6% | 13.0% | 10.7% |
Return vs Industry: EURI B underperformed the Swedish Biotechs industry which returned 13.3% over the past year.
Return vs Market: EURI B underperformed the Swedish Market which returned 9.9% over the past year.
Price Volatility
EURI B volatility | |
---|---|
EURI B Average Weekly Movement | 32.3% |
Biotechs Industry Average Movement | 8.9% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: EURI B's share price has been volatile over the past 3 months.
Volatility Over Time: EURI B's weekly volatility (32%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 2 | Kirstin Kriz | www.euris.org |
European Institute of Science AB (publ) manufactures and sells diagnostic assays for the clinical laboratory and point-of-care settings, and point-of-care instrumentation for diagnostic applications in Sweden. It primarily focuses on the diagnostic assays and instrumentation for canine, feline, and equine animals. The company’s products include TurboReader point-of-care instruments that performs measurements using disposable cuvettes; Canine C-Reactive (CRP) TurboReader assays for the quantitative determination of Canine CRP in dog serum or plasma; Feline Hp (Haptoglobin) TurboReader assay for determining Hp in cat serum or plasma; Feline SAA TurboReader assay for the determination of serum amyloid A (SAA) in cat serum or plasma; and Equine SAA TurboReader assay for determining SAA in horse serum or plasma.
European Institute of Science AB (publ) Fundamentals Summary
EURI B fundamental statistics | |
---|---|
Market cap | SEK 2.67m |
Earnings (TTM) | -SEK 2.65m |
Revenue (TTM) | SEK 765.87k |
3.5x
P/S Ratio-1.0x
P/E RatioIs EURI B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EURI B income statement (TTM) | |
---|---|
Revenue | SEK 765.87k |
Cost of Revenue | SEK 347.41k |
Gross Profit | SEK 418.45k |
Other Expenses | SEK 3.07m |
Earnings | -SEK 2.65m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -4.61 |
Gross Margin | 54.64% |
Net Profit Margin | -346.31% |
Debt/Equity Ratio | 0% |
How did EURI B perform over the long term?
See historical performance and comparison